Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Encorafenib + Binimetinib +/- Nivolumab for Thyroid Cancer
Recruiting1 awardPhase 2
Portland, Oregon
This trial is testing a combination of drugs to treat patients with thyroid cancer that has spread and does not respond to radioiodine treatment. The drugs may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and the immunotherapy may help the body's immune system attack the cancer.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.